Theratechnologies Scores FDA Win with EGRIFTA WR: A Leaner, Smarter Fat-Fighter for HIV Patients

March 26, 2025

DENVER, Colo., Mar 26, 2025 (247marketnews.com)- Theratechnologies (NASDAQ:THTX) notched a big victory, as the U.S. Food and Drug Administration (FDA) greenlit its EGRIFTA WR (tesamorelin F8), a revamped daily injectable to tackle excess visceral abdominal fat in adults with HIV and lipodystrophy. This new formulation, set to replace EGRIFTA SV, slashes administration volume by over half and swaps daily reconstitution for a weekly prep; a game-changer for patients and a shot at the $1 billion HIV therapeutics market.

Christian Marsolais, Ph.D., SVP and Chief Medical Officer at Theratechnologies, stated, “We are pleased to offer this improved, more convenient version of tesamorelin for injection to help people with HIV and their healthcare providers more effectively manage comorbidities like lipodystrophy, which today often presents as central adiposity. EGRIFTA WR enables a simplified administration and an improved patient experience, which are important considerations for people living with HIV.”

EGRIFTA WR remains the only FDA-approved fix for this stubborn fat buildup, a common lipodystrophy woe. Unlike EGRIFTA SV (F4), which demands daily mixing, WR’s weekly reconstitution and slim 0.16 mL dose (1.28 mg) streamline the routine. Packed in four single-use vials, each with 11.6 mg for seven doses, it’s room-temp friendly (68°-77°F) pre- and post-mix. Pharmacokinetic data confirm it matches the original EGRIFTA (F1) punch, with side effects like joint pain, injection site reactions, and swelling topping the list.

David Alain Wohl, MD, Professor at the Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, added, “Central adiposity, characterized by the accumulation of excess visceral abdominal fat (EVAF), is a common complication for people with HIV that may result from the virus itself, from certain older antiretrovirals and from a reduction in growth hormone concentrations. Given the significant impact of EVAF on health and quality of life for many of our patients with HIV, and the importance of maintaining lean muscle mass especially as we age, a new, more conveniently dosed formulation of tesamorelin is a welcome advancement.”

Patent-protected until 2033, it’s poised to phase out EGRIFTA SV.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (THTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.